JP7791559B2 - Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤 - Google Patents

Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤

Info

Publication number
JP7791559B2
JP7791559B2 JP2025534818A JP2025534818A JP7791559B2 JP 7791559 B2 JP7791559 B2 JP 7791559B2 JP 2025534818 A JP2025534818 A JP 2025534818A JP 2025534818 A JP2025534818 A JP 2025534818A JP 7791559 B2 JP7791559 B2 JP 7791559B2
Authority
JP
Japan
Prior art keywords
ebv
epstein
barr virus
disease
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025534818A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025105377A5 (https=
JPWO2025105377A1 (https=
Inventor
誠二 景山
亨輔 金井
裕規 吉山
久 飯笹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tottori University NUC
Shimane University NUC
Original Assignee
Tottori University NUC
Shimane University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tottori University NUC, Shimane University NUC filed Critical Tottori University NUC
Publication of JPWO2025105377A1 publication Critical patent/JPWO2025105377A1/ja
Publication of JPWO2025105377A5 publication Critical patent/JPWO2025105377A5/ja
Application granted granted Critical
Publication of JP7791559B2 publication Critical patent/JP7791559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2025534818A 2023-11-13 2024-11-12 Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤 Active JP7791559B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023193086 2023-11-13
JP2023193086 2023-11-13
PCT/JP2024/040210 WO2025105377A1 (ja) 2023-11-13 2024-11-12 Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤

Publications (3)

Publication Number Publication Date
JPWO2025105377A1 JPWO2025105377A1 (https=) 2025-05-22
JPWO2025105377A5 JPWO2025105377A5 (https=) 2025-10-15
JP7791559B2 true JP7791559B2 (ja) 2025-12-24

Family

ID=95742274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025534818A Active JP7791559B2 (ja) 2023-11-13 2024-11-12 Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤

Country Status (2)

Country Link
JP (1) JP7791559B2 (https=)
WO (1) WO2025105377A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181118A1 (en) 2015-12-14 2017-06-21 Warszawski Uniwersytet Medyczny Synergistic combination of txnr inhibitors and ascorbate for treatment of b cell malignancies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181118A1 (en) 2015-12-14 2017-06-21 Warszawski Uniwersytet Medyczny Synergistic combination of txnr inhibitors and ascorbate for treatment of b cell malignancies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAKRAVARTY S., et al.，Autographic checks and balances of cellular immune responses，Autography Reports，2022年，Vol. 1, No. 1，pp. 83-87
EWEAS, A. F., et al.，Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-Cov-2，Current Issues in Molecular Biology，2022年07月04日，Vol. 44，pp. 3018-3029
LIU W., et al.，Structures of capsid and capsid-associated tegument complex inside the Epstein-Barr virus，Nature Microbiology，2020年10月，Vol. 5，pp. 1285-1298
TEITELL, M.A., et al.，TCL1 Expression and Epstein-Barr Virus Status in Pediatric Burkitt Lymphoma，American Journal of Clinical Pathology，2005年，Vol. 124, Issue 4，pp. 569-575
WANG, L.W., et al.，Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation，Cell Metabolism，2019年，Vol. 30, Issue 3，pp. 539-555

Also Published As

Publication number Publication date
WO2025105377A1 (ja) 2025-05-22
JPWO2025105377A1 (https=) 2025-05-22

Similar Documents

Publication Publication Date Title
Prichard et al. The development of new therapies for human herpesvirus 6
Pagano et al. Acyclovir and Epstein—Barr virus infection
Reefschlaeger et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action
EP2516629B1 (en) Herpes simplex virus vaccines
WO2003050129A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
CN114796177A (zh) 抗冠状病毒药物和应用
AU2001270631B2 (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
Ida et al. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants
JP7791559B2 (ja) Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス複製阻害剤
Biswas et al. High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1
Ghosh et al. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents
JP5326173B2 (ja) エプスタイン・バールウイルス関連疾患に対する薬剤およびそのスクリーニング法
CN118806781B (zh) 淫羊藿次苷i在制备抗病毒药物中的应用
EP3271020B1 (en) Reversal of latency of retroviruses with a galectin protein
JPH05507719A (ja) 薬学的治療
JP2025003012A (ja) ヘルペスウイルスの感染に起因する疾患の予防又は治療のための医薬組成物
Sankar et al. PARP in the neuropathogenesis of cytomegalovirus infection–Possible role and therapeutic perspective
CN116392482A (zh) Bms-265246在制备抗疱疹病毒药物中的应用和药物组合物
CN116115757A (zh) 疱疹病毒的细胞宿主因子ClC-2在制备抗疱疹病毒药物中的应用
CN112294834B (zh) 地西他滨在制备治疗单纯疱疹病毒的药物中的应用
CN117860811B (zh) 一种火炭母提取物及其在制备抗i型单纯疱疹病毒药物中的应用
Donaldson et al. Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells
KR101259688B1 (ko) 안젤리신을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
Egilmezer et al. Antiviral efficacy versus host recovery: contrasting transcriptional footprints of four antivirals in human cytomegalovirus-infected brain organoids
JPH11322746A (ja) 抗ヘルペスウイルス剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250613

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251204

R150 Certificate of patent or registration of utility model

Ref document number: 7791559

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150